Clinical trial
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque…
NCT00336973 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00336973 |
|---|---|
| Title | A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent |
| Official title | A Phase IV Open-Label Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Raptiva (Efalizumab) in Adult Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | efalizumab |
| Enrollment | 73 |
| Start date | May 1, 2006 |
| Primary completion | Feb 1, 2008 |
| First posted | Jun 15, 2006 |
| Last update posted | Jul 23, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: